Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Scopus BioPharma Inc (NASDAQ:SCPS) has launched Duet Therapeutics that integrates the management and clinical development of the immunotherapy assets of Scopus and Olimmune.
- Related Content: Scopus BioPharma Adds Oligonucleotide Cancer Therapeutics With Olimmune Acquisition.
- The Duet Platform is comprised of three technologies, including RNA silencing (DUET-01), Antisense (DUET-02), and Protein degradation (DUET-03).
- DUET-01 is in Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma.
- In 2022, Duet is targeting to file two INDs for DUET-02 in two separate indications: genitourinary and head & neck cancers.
- Duet is also evaluating combination therapies with checkpoint inhibitors.
- Price Action: SCPS stock is up 30.50% at $6.54 during the market session on the last check Thursday, before the trading was halted.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!